Background Cross-talk between skin keratinocytes (KCs) and Langerhans cells (LCs) plays a fundamental role in the body's first line of immunological defences. However, the mechanism behind the interaction between these two major epidermal cells is unknown. Interleukin (IL)-32 is produced in inflammatory skin disorders. We questioned the role of IL-32 in the epidermis. Objectives We aimed to determine the role of IL-32 produced by KCs on surrounding LCs. Methods We used an ex vivo human explant model from healthy donors and investigated the role of IL-32 on LC activation using imaging, flow cytometry, reverse transcriptase quantitative polymerase chain reaction and small interfering (si)RNA treatment. Results Modified vaccinia virus ankara (MVA) infection induced KC death alongside the early production of the proinflammatory cytokine IL-32. We demonstrated that IL-32 produced by MVA-infected KCs induced modest but significant morphological changes in LCs and downregulation of adhesion molecules, such as epithelial cell adhesion molecule and very late antigen-4, and CXCL10 production. The treatment of KCs with IL-32-specific siRNA, and anti-IL-32 blocking antibody significantly inhibited LC activation, demonstrating the role of IL-32 in LC activation. We also found that some Toll-like receptor ligands induced a very high level of IL-32 production by KCs, which initiated LC activation. Conclusions We propose, for the first time, that IL-32 is a molecular link between KCs and LCs in healthy skin, provoking LC migration from the epidermis to the dermis prior to their migration to the draining lymph nodes.
What does this study add?
• We questioned the role of IL-32 in LC behaviour in response to external stimuli.
• Keratinocytes produce IL-32 in response to danger signals in nonpathological skin.
The level of IL-32 production is dependent on Toll-like receptor ligand stimulation pathways.
• IL-32 produced by keratinocytes promotes the initial steps of LC migration from the epidermis to the dermis.
• This step contributes to LC activation, decreased surface expression of adhesion molecules and a slight but significant increase in CXCL10 production.
What is the translational message?
• Our work proposes that IL-32 is a molecular link between keratinocytes and LCs in healthy skin, which could be exacerbated in pathological conditions during skin barrier disruption such as atopic dermatitis, hidradenitis suppurativa and alopecia areata.
Epidermal cells play a fundamental role in cutaneous innate immunity, providing both a physical barrier via tight junction formation and a chemical barrier via the production of antimicrobial peptides and proteases.
1,2 CD45 À keratinocytes (KCs) comprise up to 90% of this epidermal cell population, where they exist alongside the more scarce Langerhans cell (LC) population (1-5% of total epidermal cells), 3 which are specialized antigen-presenting cells characterized by CD45, CD1a, CD1c and human leucocyte antigen (HLA)-DR expression. Together, KCs and LCs form a strong barrier to fight pathogen entry. Skin barrier disruption provokes the local production of proinflammatory cytokines and chemokines by KCs, bridging innate immunity to adaptive immunity via LCs. 4, 5 In this regard, the production of cytokines and chemokines by KCs and LCs has been observed in many skin disorders [6] [7] [8] [9] and more particularly, the production of interleukin (IL)-32, a proinflammatory cytokine produced by KCs. 10, 11 However, the impact of local production of IL-32 on LCs has not been explored. Here, we questioned whether IL-32 produced by KCs could impact the behaviour of LCs during microbial insults. LC activation is characterized by the upregulation of costimulatory molecules such as CD80 and HLA-DR in addition to the release of proinflammatory cytokines and chemokines including CXCL10. [12] [13] [14] Furthermore, activated LCs change their morphology by the shortening of dendrite size in response to modified vaccinia virus ankara (MVA) intradermal administration. 15 So-called 'en route' LCs start migrating to the draining lymph nodes. 15 They also exhibit an altered expression of adhesion molecules, including very late antigen (VLA)-4, epithelial cell adhesion molecule (EpCam) and Ecadherin. [16] [17] [18] We recently demonstrated that LC migration from skin to the draining lymph nodes allows for the priming of CD4 and CD8 responses observed after intradermal and transcutaneous application of vaccines. [19] [20] [21] [22] However, local epidermal events initiating the activation of LCs remain to be studied. Herein, we used a human skin explant model to investigate the role of a proinflammatory cytokine, IL-32, as a molecular link between stimulated KCs and LCs. We demonstrated that IL-32 leads to LC activation as shown by morphological changes, detachment from the epidermal layer and the production of chemotactic CXCL10.
Materials and methods

Human skin explant collection and preparation
Human skin samples were obtained from healthy volunteers undergoing plastic surgery for breast, abdomen or facelift (Service de Chirurgie Plastique, Reconstructrice et Esth etiqueCentre de Traitement des Brûl es, Saint-Louis Hospital, Paris, France and Centre de Chirurgie Plastique et Reconstructrice, Tenon Hospital, Paris, France). All skin samples were taken after informed consent was provided according to the local Institutional Ethics Committee guidelines (IRB 00003835) and ethical rules stated in the Declaration of Helsinki principles. Immediately after surgical excision, skin samples were conserved in NaCl and processed rapidly.
Skin administration
Skin explant intradermal injections were performed using the Mantoux method. For transcutaneous immunization, cyanoacrylate skin surface stripping was performed as previously described. 19 Wild-type MVA was obtained from R. Wagner (University of Regensburg, Regensburg, Germany) and was used at 10 7 plaque-forming units (PFU) per cm 2 of skin.
Pam3CSK4 and imiquimod Toll-like receptor ligands (Invivogen, San Diego, CA, U.S.A.), human IL-32 blocking antibody (R&D, Minneapolis, MN, U.S.A.) and recombinant human (rh)IL-32c (R&D) were used as indicated.
Human skin cell suspension
Fresh skin samples were prepared as previously described in order to separate epidermal sheets from the dermis. 15 
Immunohistology
Treated skin tissue samples, and untreated skin as a negative control, were frozen in OCT compound (Tissue-Tek, Sakura, Leiden, Belgium) for cryopreservation, and cryosections of 5 lm were prepared with a Microm HM550 cryostat (Microm Microtech, Brignais, France) and fixed as previously described. 15 Slides of skin sections, epidermal sheets and epidermal cells were stained as previously described using anti-CD1a (Dako products, Agilent Technologies, Santa Clara, CA, U.S.A.), anti-IL-32abcd (Biolegend) and antihuman apoptosis-associated speck-like protein containing CARD (ASC) (Santa Cruz, Dallas, TX, U.S.A.) and isotype-matched control antibody in phosphate-buffered saline (PBS)-BSA-0Á1% saponin. Slides were washed with PBS 1X followed by goat antimouse IgG1-, IgG2a-Alexa Fluor 488, 594 and 647 (Invitrogen) and goat antirabbit IgG-Alexa Fluor 488 and 594 (Invitrogen) incubation, and mounted with Vectashield mounting medium containing DAPI (4 0 ,6-diamidino-2-phenylindole) (Vector Laboratories, Burlingame, CA, U.S.A.). Slides were analysed using BX51 Olympus and Axio Z1 Zeiss fluorescence microscopes and with image processing and analysis software (Qimaging and Zen, Media Cybernetics Inc., Silver Spring, MD, U.S.A.) respectively. All images were processed using ImageJ software.
Statistical analysis
As the sample size was small in our analyses, we used a nonparametric test. We used a Wilcoxon matched paired signedrank test to assess the significance of modifications induced per individual or unpaired Mann-Whitney U-test to assess the significance of modifications induced per group for independent samples. Our hypotheses regarding the increased activation and decreased adhesion markers expressed on LCs, and also regarding the changing morphology to activated round LCs, were tested in one direction. As we had a limited number of human samples and we considered the consequences of missing an effect in the untested direction to be negligible, we used one-tailed tests. For comparisons of more than two groups, one-way Friedman test or Kruskal-Wallis test with Dunn's correction was applied before paired (Figs 1d, 3a, d) or unpaired tests (Figs 2b, 3b), respectively. Results are presented as median with interquartile range. Significance was set at one-sided P-value < 0Á05. Prism 6 software was used for data handling, analysis and graphic representations.
Results
Interleukin-32 produced by modified vaccinia virus ankara-infected keratinocytes contributes to rapid activation of Langerhans cells promoting CXCL10 production
We have previously demonstrated that epidermal exposure to MVA resulted in dendrite retraction on CD1a + LCs and their activation. 15 We hypothesized that cytokines released by KCs could impact LC activation. To explore the involved mechanism further, we sorted KCs from the epidermal layer of fresh human skin and infected them with MVA (1 PFU per cell) 3 h prior to the addition of LCs (Fig. 1a) . We investigated the expression of CD80 costimulatory molecules, HLA-DR high in addition to CXCL10 production, which are indicators of LC activation in response to danger signals as previously described. 12, 14, 24, 25 We observed a significant increase in the percentage of CXCL10-producing LCs along with a slight but significant increase in CD80 and HLA-DR high expression at 24 h after coculture of LCs with MVA-treated KCs compared with controls (Fig. 1a , n = 6 donors; P < 0Á05). These data were confirmed by reverse transcriptase quantitative polymerase chain reaction and revealed that among CXCR3-binding chemokines (CXCL4, CXCL9, CXCL10 and CXCL11) only CXCL10 was significantly higher in the epidermis (data not shown).
KCs are known to produce proinflammatory factors, including IL-32, in atopic dermatitis (AD). 10 Using immunofluorescence microscopy, we found that CD1a À KCs produced IL-32 at 4 h post-MVA infection compared with control medium (Fig. 1b) . We did not detect any IL-32 in CD1a + LCs in these conditions (Fig. 1b) . The frequency of IL-32-producing KCs was counted and represented in Figure 1c . We found an approximatively twofold increase in IL-32 production by KCs following MVA stimulation (Fig. 1c , n = 5 donors; P < 0Á05). In order to block IL-32 production, epidermal cells were treated with siRNA targeting IL-32 or scrambled RNA control prior to MVA stimulation ( Fig. S1 ; see Supporting Information). We found that IL-32-specific siRNA ( Figure S1b . In addition, we confirmed analysis. Data are represented using box and whisker plots with median (min/max). For comparisons of more than two groups, Friedman test was applied before one-tailed Wilcoxon matched paired signed-rank test. *P < 0Á05.
that KCs (Fig. S1c , left panel, six donors) significantly increased IL-32 expression following MVA stimulation, but LCs did not (Fig. S1c right panel, six donors) . This expression was inhibited by IL-32-specific siRNA treatment compared with scrambled siRNA. Thus, compared with scrambled siRNA, IL-32-specific siRNA treatment significantly decreased the proportion of IL-32+ KCs in a dose-dependent manner. Finally, we then examined the effect of IL-32-specific siRNA treatment of epidermal cells on CXCL10 production by LC activation (Fig. 1d) . We found a significant decrease of CXCL10-producing LCs after IL-32-specific siRNA treatment at 24 h following MVA infection compared with scrambled siRNA by flow cytometry analysis (Fig. 1d , n = 6 donors; P < 0Á05).
Thus, the modest IL-32 production by KCs induced LC activation as assessed by CXCL10 production, which is abrogated by IL-32 siRNA treatment.
Interleukin-32 induces detachment of Langerhans cells from the epidermal layer allowing for their migration
We then evaluated the impact of rhIL-32c protein and MVA treatment compared with PBS treatment of epidermis on LC morphology using immunofluorescence microscopy (Fig. 2a, All data are represented using box and whisker plots with median (min/max). For comparisons of more than two groups, Kruskal-Wallis test was applied before one-tailed Mann-Whitney U-test. ****P < 0Á0001, **P < 0Á01, *P < 0Á05. (Fig. 2b , three donors, five fields). Skin treatment with anti-IL32 antibody (0Á1 lg mL À1 ) (Fig. 2a, b) significantly inhibits LC activation, but treatment with isotype control antibodies does not ( Fig. S2 ; see Supporting Information). We have previously demonstrated that such shape changes represent an early activation step prior to the migration of LCs to the dermis and draining lymph nodes for CD8 + T-cell priming. 15 A critical step in this process is the regulation of adhesion molecules on the surface of the LCs, permitting their detachment from the KC layers. As shown in Figure 2c , IL-32c induced a significant downregulation of LC surface expression of EpCam (Fig. 2c , left panel, n = 5 donors; P < 0Á05) and VLA-4 expression (Fig. 2c , right panel, n = 5 donors; P < 0Á05) at 4 h post-rhIL-32c treatment of epidermal cells. We did not observe any modulation of these adhesion molecules on KCs (data not shown). E-cadherin expression on KCs and LCs was also analysed, but did not exhibit any significant changes (data not shown).
Collectively, we demonstrated that IL-32c plays a crucial role in the activation of LCs, expression of adhesion molecules and morphological modifications allowing for the acquisition of the 'en route' LC phenotype.
Innate sensors induce interleukin-32 production by keratinocytes together with morphological changes of Langerhans cells and CXCL10 production
We found that MVA treatment had a significant but modest effect on IL-32 production. Thus, we examined the effect of TLR agonists on IL-32 production by KCs (Fig. 3a) and consequently on LC morphological modification (Fig. 3b, c) . Surprisingly, TLR-1/2 (Pam3CSK4), TLR-7 (imiquimod) and TLR-4 (LPS) agonist treatment induced a significant increased expression of IL-32 by KCs, shown by flow cytometry analysis (Fig. 3a , n = 6 donors; P < 0Á05). These TLR agonists induced an average of a threefold to 16-fold increase in IL-32 production by KCs. IL-32 production was lower after flagellin, ssRNA and Poly(I:C) stimulation (Fig. 3a) .
We also showed that both Pam3CSK4 and imiquimod induced a significant increase in the number of round-shaped LCs (Fig. 3b, three donors, five fields) . However, one cannot exclude the direct effect of TLR agonists on LCs during epidermal layer treatments. In order to confirm the effect of IL-32 on LCs during TLR ligand stimulation, skin explants were treated with anti-IL-32 blocking antibodies together with TLR ligand treatment (Pam3CSK4 and imiquimod). Representative immunostaining is shown for each condition in Figure 3c . Anti-IL-32 blocking antibodies significantly restored dendritic LC morphology following either intradermal or transcutaneous administration of MVA compared with controls (Fig. 3c) . The fact that IL-32c-treated epidermis also induced morphological changes in LCs (as shown in Fig. 2a ) strongly suggests that the TLR ligand effect on IL-32 production on KCs would, in turn, activate LCs.
In order to test the impact of KCs treated with TLR agonists on LC activation (production of CXCL10), we sorted KCs and LCs prior to treatment (Fig. 3d) . CXCL10 production by LCs was modest but significantly higher when KCs were treated with Pam3CSK4 compared with untreated controls (Fig. 3d , seven donors; P < 0Á05). The percentage of LCs expressing CXCL10 is similar to that seen in MVA treatment (Fig. 1) . These results indicate that IL-32 production by KCs and subsequent LC activation may be elicited by specific pathogen-associated molecular pattern receptor activation in addition to MVA infection and could be a feature of the skin's reaction to innate sensors.
Discussion
IL-32 production in the skin has been observed in inflammatory skin disorders such as AD, alopecia areata and hidradenitis suppurativa, suggesting that IL-32 production plays a critical role in skin diseases. 10, 11, 26 To improve the understanding of molecular mechanisms that allow LC activation in the epidermal layers, we have investigated the role of IL-32 in the epidermis. We first showed that KCs are the major cell population that produces IL-32 in the skin. We demonstrated, All data are represented using box and whisker plots with median (min/max) (n = 3 donors, five fields for each donor). For comparisons of more than two groups, Kruskal-Wallis test was applied before Mann-Whitney U-test. ****P < 0Á0001, ***P < 0Á001, **P < 0Á01, *P < 0Á05. (d) KCs and LCs were separately analysed by cell sorting. Isolated KCs were treated with imiquimod, Pam3CSK4 and medium. Cells were washed prior to coculture with LCs. CXCL10 + producing LCs (ViViD À CD45 + CD1c + cells) were analysed at 24 h by flow cytometry. All data are represented using a box and whisker plot with median (min/max) for n = 6 donors. For comparisons of more than two groups, Friedman test was applied before one-tailed Wilcoxon matched paired signed-rank test. *P < 0Á05. PBS, phosphatebuffered saline (PBS).
for the first time, that the stimulation of KCs by MVA and several TLR agonists induces IL-32 production that, in turn, promotes LC activation as assessed by CXCL10 production, morphological changes and downregulation of cellular adhesion molecules. We showed that IL-32-specific siRNA in KCs strongly inhibited IL-32 expression and consequently LC activation. While our manuscript was under review, Gorvel et al.
27
showed that LCs expressed IL-32 while in a 'steady state'. However, the method they used for LC isolation is quite different from ours. Gorvel et al. 27 isolated LCs following 48 h of migration outside the skin, in contrast to the enzymatic digestion of skin cells used in our model. Their method allows LC migration from the skin, which is often associated with activation and the IL-32 release can be observed. In our skin explant model, which reflects a condition close to steady state, KCs are the main producer of IL-32 at an early time point following stimulation.
As proposed by others, 28 Figure S3d . In conclusion, three methods of analysis of apoptotic cells, i.e. ASC, annexin V and TUNEL, using in vitro and ex vivo skin epidermal cells, showed that MVA treatment induced apoptosis of KCs. Measurement of IL-32 by enzyme-linked immunosorbent assay showed slight cytokine production under these conditions, which suggests its release in the skin microenvironment (Fig. S3e) . Through the expression of innate receptors, KCs and LCs are able to sense pathogen penetration and danger signals. 32 MyD88 deficiency in KCs directly impairs LC migration after antigen exposure, 33 demonstrating that LC migration to the dermis is directly dependent on the MyD88/nuclear factor-KB pathway in KCs. Accordingly, we found that several TLR agonists (such as Pam3CSK4/TLR1-2 and imiquimod/TLR-7) induced IL-32 production by KCs and LC activation including LC morphological modification ( Fig. S4 ; see Supporting Information). Finally, IL-32 exists in four main isoforms that originate from the splicing of the c isoform. 31, 32 Most studies on IL-32 have been performed on blood cells as illustrated by the effect of IL-32 upon blood-derived dendritic cell populations in upregulation of costimulatory molecules. 34 Although the c and b isoforms have been associated with anti-inflammatory functions including reduced cell activation and proliferation, cytotoxic function 35 and increased IL-10 production, 36 the majority of studies define a proinflammatory character for IL-32. 34, 37, 38 Finally, IL-32 has been proposed as a biomarker of skin inflammation in AD, alopecia areata and hidradenitis suppurativa. 10, 11, 26 The analysis of IL-32 isoforms mRNA expression in skin biopsies from three skin disorders (hidradenitis suppurativa, psoriasis and AD) compared with skin from healthy donors, revealed that all main IL-32 isoforms are expressed in skin, but at different levels depending on the origin of skin disorder. 11 Further studies are required to analyse the contribution of each isoform in LC activation. Meyer et al. also showed that high serum levels of IL-32 correlate with disease severity, highlighting its potential relevance in skin immunity. 10 Here, we demonstrated the role of IL-32 in LC activation, bringing new insights into the cross-talk between KCs and LCs and linking innate to adaptive immunity.
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